|
2019 Conference Publication Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplantGries, Katharine, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Orlowski, Robert Z., Bahlis, Nizar J., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Hulin, Cyrille, Weisel, Katja, He, Jianming, Ho, Kai Fai, Wang, Jim, Van Rampelbergh, Rian, Uhlar, Clarissa, Kobos, Rachel and Perrot, Aurore (2019). Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.375 |
|
2019 Conference Publication Significantly improved relative survival of patients with myeloma in Queensland with treatment advancesMollee, Peter, Harwood, Matthew, Dunn, Nathan, Moore, Julie and Hapgood, Greg (2019). Significantly improved relative survival of patients with myeloma in Queensland with treatment advances. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.387 |
|
2019 Journal Article Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceTobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458 |
|
2019 Journal Article Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltrationTobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365 |
|
2019 Journal Article Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registryHo, P. Joy, Moore, Elizabeth M., McQuilten, Zoe K., Wellard, Cameron, Bergin, Krystal, Augustson, Bradley, Blacklock, Hilary, Harrison, Simon J., Horvath, Noemi, King, Tracy, Mollee, Peter, Quach, Hang, Reid, Christopher, Rosengarten, Brian, Walker, Patricia, Wood, Erica M. and Spencer, Andrew (2019). Renal impairment at diagnosis in myeloma: Patient characteristics, treatment, and impact on outcomes. Results trom the Australia and New Zealand myeloma and related diseases registry. Clinical Lymphoma, Myeloma and Leukemia, 19 (8), e415-e424. doi: 10.1016/j.clml.2019.05.010 |
|
2019 Conference Publication Lysozyme amyloidosis – Two novel cases with newly described genetic mutationsMcMichael, L., Chang, S., Gibbs, S., Mollee, P., Gillmore, J., Horvath, N., Crail, S. and Jobert, A. (2019). Lysozyme amyloidosis – Two novel cases with newly described genetic mutations. ISN World Congress of Nephrology (WCN) 2024, Buenos Aires, Argentina, 13-16 April 2024. New York, NY United States: Elsevier. doi: 10.1016/j.ekir.2019.05.590 |
|
2019 Journal Article High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapyTate, Courtney, Burgess, Melinda, McMillan, Nigel A., Saunders, Nicholas A., Cheung, Catherine, Gill, Devinder and Mollee, Peter (2019). High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy. Leukemia and Lymphoma, 60 (10), 1-5. doi: 10.1080/10428194.2019.1581936 |
|
2019 Conference Publication Validation of the Boston University staging system in AL amyloidosisTomlinson, R., Matigain, N. and Mollee, P. (2019). Validation of the Boston University staging system in AL amyloidosis. 29th European Hematology Association Congress EHA24, Madrid, Spain, 13-16 June 2024. Philadelphia, PA United States: Wiley. doi: 10.1097/01.hs9.0000567024.85321.eb |
|
2019 Journal Article The epidemiology of amyloidosis in Queensland, AustraliaWisniowski, Brendan, McLeod, Donald, Adams, Rebecca, Harvey, Yasmin, Brown, Ian, McGuire, Lloyd, Armes, Jane and Mollee, Peter (2019). The epidemiology of amyloidosis in Queensland, Australia. British Journal of Haematology, 186 (6) bjh.16000, 829-836. doi: 10.1111/bjh.16000 |
|
2019 Journal Article Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaFacon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z., Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O'Dwyer, Michael, Perrot, Aurore, Venner, Christopher P., Weisel, Katja, Mace, Joseph R., Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M., Kobos, Rachel, Qi, Ming ... Mollee, Peter (2019). Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. The New England Journal of Medicine, 380 (22), 2104-2115. doi: 10.1056/NEJMoa1817249 |
|
2019 Journal Article Validation of the Boston University staging system in AL amyloidosisTomlinson, Ross, Matigian, Nicholas and Mollee, Peter (2019). Validation of the Boston University staging system in AL amyloidosis. Amyloid: Journal of Protein Folding Disorders, 26 (3), 1-3. doi: 10.1080/13506129.2019.1608941 |
|
2019 Conference Publication The epidemiology of amyloidosis in AustraliaWisniowski, Brendan, McLeod, Donald, Adams, Rebecca, Harvey, Yasmin, Armes, Jane, Papadimos, David, Brown, Ian, McGuire, Lloyd and Mollee, Peter (2019). The epidemiology of amyloidosis in Australia. XVI International Symposium on Amyloidosis, Kumamoto, Japan, 26-29 March 2018. Abingdon, Oxfordshire United Kingdom: Taylor & Francis. doi: 10.1080/13506129.2019.1582481 |
|
2019 Journal Article Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvementChin, C. K., Tsang, E., Mediwake, H., Khair, W., Biccler, J., Hapgood, G., Mollee, P., Nizich, Z., Joske, D., Radeski, D., Cull, G., Villa, D., El-Galaly, T. C. and Cheah, C. Y. (2019). Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement. British Journal of Haematology, 184 (5), 826-828. doi: 10.1111/bjh.15173 |
|
2019 Journal Article Report of the survey conducted by RCPAQAP on current practice for paraprotein and serum free light chain measurement and reporting: A need for harmonisationWijeratne, Nilika, Tate, Jillian R., Wienholt, Louise and Mollee, Peter (2019). Report of the survey conducted by RCPAQAP on current practice for paraprotein and serum free light chain measurement and reporting: A need for harmonisation. Clinical Biochemist Reviews, 40 (1), 31-42. |
|
2019 Journal Article Proposed addendum to 2012 recommendations for standardised reporting of protein electrophoresis in Australia and New ZealandTate, Jillian R., Smith, Joel D., Wijeratne, Nilika and Mollee, Peter (2019). Proposed addendum to 2012 recommendations for standardised reporting of protein electrophoresis in Australia and New Zealand. Clinical Biochemist Reviews, 40 (1), 23-30. |
|
2019 Journal Article Response to article by Caponi et al. about serum free light chainsTate, Jillian R., Hawley, Carmel and Mollee, Peter (2019). Response to article by Caponi et al. about serum free light chains. Clinical Chemistry and Laboratory Medicine, 57 (2), e1-e2. doi: 10.1515/cclm-2018-0994 |
|
2019 Conference Publication Beta-migrating paraproteins: a need for harmonisation of reportingWijeratne, Nilika, Tate, Jillian R., Du Toit, Stephen, Smith, Joel D., Soepnel, Andrew, Choy, Kay Weng, Martin, Helen, Henry, Robyn, Glegg, Kaye, Byrnes, Elizabeth, Wienholt, Louise and Mollee, Peter (2019). Beta-migrating paraproteins: a need for harmonisation of reporting. Pathology Update 2019, Melbourne, VIC Australia, 22-24 February 2019. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2018.12.323 |
|
2019 Journal Article Paraprotein sample exchange in Australia and New Zealand - 2018Wijeratne, Nilika, Tate, Jillian R., Toit, Stephen Du, Smith, Joel D., Soepnel, Andrew, Choy, Kay Weng, Martin, Helen, Henry, Robyn, Glegg, Kaye, Byrnes, Elizabeth, Wienholt, Louise and Mollee, Peter (2019). Paraprotein sample exchange in Australia and New Zealand - 2018. Clinical Biochemist Reviews, 40 (1), 43-54. |
|
2019 Journal Article Amyloidosis in AustraliaMollee, Peter, Gibbs, Simon and Stewart, Graeme (2019). Amyloidosis in Australia. Expert Opinion on Orphan Drugs, 7 (2), 37-39. doi: 10.1080/21678707.2019.1563539 |
|
2019 Conference Publication Development of an individualized, supervised exercise intervention as standard care for patients with Multiple MyelomaNicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma. 17th International Myeloma Workshop, Boston, MA, United States, 12-15 September 2019. New York, United States: Elsevier. doi: 10.1016/j.clml.2019.09.355 |
